Windtree Therapeutics Makes $520 Million Bet on Cryptocurrency, Faces Scrutiny Over Priorities.

Download IPFS

Windtree Therapeutics Inc. (NASDAQ: WINT), a U.S.-based biotechnology company, has entered into funding agreements totaling up to $520 million, with the majority reportedly intended for the purchase of BNB cryptocurrency. The move signals a major shift in strategy and has drawn attention from industry observers concerned about the company’s focus and direction.

According to company announcements, the funding includes a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp., a digital asset investment firm. Windtree stated that, pending shareholder approval to increase its authorized common stock, the proceeds would support its cryptocurrency acquisition strategy. Unverified estimates indicate that as much as 99% of the funding may be directed toward BNB, though formal confirmation is pending regulatory filings.

“We are excited to incorporate these new facilities to enable our future BNB acquisitions,” said Windtree CEO Jed Latkin in a recent statement. He noted that stockholder approval remains a requirement before accessing the equity line.

Build and Build Corp., co-founded by Patrick Horsman, Joshua Kruger, and Johnathan Pasch, has positioned itself as a partner for companies seeking to expand into digital assets. Horsman stated that the agreement gives Windtree “flexibility and scale” to pursue its strategy.

Windtree has described itself as a diversified company operating both a therapeutic pipeline and a digital asset treasury. However, the size of the proposed cryptocurrency allocation has raised questions among financial analysts and stakeholders about the company’s long-term priorities. The strategic focus on BNB, a cryptocurrency associated with Binance, comes amid ongoing regulatory scrutiny of the digital asset sector and broader economic uncertainty.

The proposed funding arrangements remain subject to U.S. Securities and Exchange Commission (SEC) oversight, and the company has acknowledged risks related to shareholder approval and market volatility.

Windtree previously focused on developing therapies for acute cardiovascular and pulmonary conditions. The firm’s sharp pivot toward digital assets has prompted debate about whether it can maintain its biotech mission while pursuing aggressive financial innovation.

In the current economic climate, marked by inflation and cautious investor sentiment, Windtree’s strategy may face continued examination. As regulatory processes unfold and shareholders weigh in, the company’s ability to balance financial diversification with pharmaceutical responsibility will likely play a critical role in its future trajectory.